Trump announces trade deal with EU following months of negotiations
Oppenheimer has maintained its Outperform rating and $35.00 price target on Avalo Therapeutics Inc. (NASDAQ: NASDAQ:AVTX), following the announcement of the first patient being dosed in the Phase 2 LOTUS trial.
The study is focused on AVTX-009, a monoclonal antibody for the treatment of hidradenitis suppurativa (HS), a chronic skin condition.
The LOTUS trial will involve 180 participants with moderate-to-severe HS to assess the effectiveness of the treatment. The key measure of success will be the proportion of patients achieving a 75% reduction in inflammatory nodules and abscesses, known as HiSCR75. The treatment will be administered subcutaneously either every two weeks or every four weeks over a 16-week period, followed by subsequent monitoring of the patients.
Avalo Therapeutics' AVTX-009 is designed to inhibit IL-1β, a protein that plays a significant role in various inflammatory disorders. The randomized study aims to provide critical data on the drug's efficacy and safety in treating HS.
Top-line data from the LOTUS trial is expected to be available in 2026. Additionally, there is anticipation for further development plans for AVTX-009 in another inflammation and immunology (I&I) indication, which may be announced later this year or in early 2025.
In other recent news, Avalo Therapeutics has initiated a Phase 2 clinical trial, LOTUS, for its investigational drug AVTX-009, aiming to treat hidradenitis suppurativa, a chronic inflammatory skin condition. This trial, which will involve approximately 180 adults, is expected to yield topline results in 2026.
Additionally, Avalo Therapeutics has regained compliance with Nasdaq's Market Value of Listed Securities Standard, a significant achievement following a previous notification of non-compliance. This development is accompanied by strategic changes within the company, including the appointment of Mittie Doyle as the new Chief Medical Officer and Paul Varki as the new Chief Legal Officer.
Avalo Therapeutics has also expanded its equity incentive and employee stock purchase plans, with amendments approved by its stockholders. These changes include an increase in the total number of shares reserved for issuance, with automatic annual increases planned through January 1, 2034.
The recent developments at Avalo Therapeutics have attracted the attention of Oppenheimer, which maintained an Outperform rating on the company. This rating is based on the potential of AVTX-009 and the company's strategic initiatives.
InvestingPro Insights
As Avalo Therapeutics (NASDAQ: AVTX) progresses with its Phase 2 LOTUS trial for AVTX-009, investors should consider some key financial metrics and insights from InvestingPro. The company's market capitalization stands at $92.52 million, reflecting its current valuation in the biotech sector.
InvestingPro Tips highlight that Avalo holds more cash than debt on its balance sheet, which could be crucial for funding ongoing clinical trials and research. However, the company is quickly burning through cash, a common characteristic of biotech firms in the development stage. This cash burn rate is particularly relevant given the expected timeline for the LOTUS trial results in 2026.
The company's financial health is further illuminated by its revenue of $0.81 million in the last twelve months, with a significant revenue decline of -95.24%. This substantial decrease underscores the importance of the AVTX-009 trial and potential future indications for the company's growth prospects.
Investors should note that analysts do not anticipate the company to be profitable this year, which is not uncommon for biotech companies with products in clinical trials. The stock has shown a strong return of 27.41% over the last month, possibly reflecting market optimism about the LOTUS trial initiation.
For those seeking a more comprehensive analysis, InvestingPro offers 11 additional tips for AVTX, providing a deeper understanding of the company's financial position and market performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.